11 clinical trials that will shape medicine in 2023

[Farooqji]

nature.com/articles/s41591-...

[Nivrac77--]

It’s interesting that the current clinical trial at Stanford using tactile stimulation gloves to slow, even stop progression of Parkinson’s and headed up by Dr. Tass and his lab is not mentioned. Is big Pharma editing the entries considered?

[Sydney75]

Gee I hope they don't figure out a way to charge lots $$$ for a repurposed older drug.

Roger Albin: For both purely scientific issues and clinical practice issues, the phase 3 trial for exenatide in Parkinson’s disease is a very attractive trial. It has the big advantage of being a repurposed drug that is already widely used in older patients. If there were a positive result, it is something that could be really adopted into clinical practice in a very practical way. The drug had reasonable preclinical data and some promising phase 2 data, and in the Parkinson’s disease world, in which there is not an animal model for really great predictive validity, this is probably about as good as it gets. The community is looking for unequivocal results, whether positive or negative. A clear positive response would be great, but a clear negative response is actually just as important.

Roger Albin is a professor of neurology and co-director of the Movement Disorders Clinic in the Department of Neurology at the University of Michigan Medical School.